Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.44
-0.45 (-6.53%)
At close: Aug 20, 2026, 4:00 PM EDT
6.78
+0.34 (5.28%)
After-hours: Aug 20, 2026, 5:55 PM EDT
Aligos Therapeutics Revenue
Aligos Therapeutics had revenue of $27.78M in the quarter ending June 30, 2026, with 2,778.55% growth. This brings the company's revenue in the last twelve months to $31.52M, up 893.01% year-over-year. In the year 2025, Aligos Therapeutics had annual revenue of $2.19M, down -44.59%.
Revenue (ttm)
$31.52M
Revenue Growth
+893.01%
P/S Ratio
1.30
Revenue / Employee
$384,366
Employees
82
Market Cap
40.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.19M | -1.76M | -44.59% |
| Dec 31, 2024 | 3.95M | -11.58M | -74.60% |
| Dec 31, 2023 | 15.53M | 1.62M | 11.66% |
| Dec 31, 2022 | 13.91M | 9.55M | 219.04% |
| Dec 31, 2021 | 4.36M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.62M |
| Veru Inc. | 16.89M |
| Metagenomi Therapeutics | 13.56M |
| Seres Therapeutics | 1.88M |
| Nutriband | 1.80M |
| Hyperion DeFi | 1.40M |
| CervoMed | 331.30K |
| Serina Therapeutics | 130.00K |
ALGS News
- 7 days ago - Aligos Therapeutics Slides: Corporate presentation - Filings
- 8 days ago - Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - GlobeNewsWire
- 14 days ago - Aligos Therapeutics Earnings release: Q2 2026 - Filings
- 14 days ago - Aligos Therapeutics Quarterly report: Q2 2026 - Filings
- 14 days ago - Aligos Therapeutics reports Q2 EPS (14c), consensus ($1.38) - TheFly
- 21 days ago - Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 - GlobeNewsWire
- 5 weeks ago - Aligos Therapeutics completes enrollment in B-SUPREME study - TheFly
- 5 weeks ago - Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection - GlobeNewsWire